Skip to content

Neuropace, Inc. NPCE Increase (Decrease) in Non-cash Interest Expense

Increase (Decrease) in Non-cash Interest Expense at other companies

Cerence Inc. logo
Cerence Inc.CRNC
$763K-48.7%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$17K-39.3%
Carlsmed, Inc. Common Stock logo
Carlsmed, Inc. Common StockCARL
$36K-33.3%
Enovis logo
EnovisENOV
$1.79M+32.6%
American Assets Trust logo
American Assets TrustAAT
$258K0.0%
Hycroft Mining Holding Corporation logo
Hycroft Mining Holding CorporationHYMC
$0-100%

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
Enterprise value$612.6M+58.1%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept npce:IncreaseDecreaseInNonCashInterestExpense.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s increase (decrease) in non-cash interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s increase (decrease) in non-cash interest expense?
Neuropace, Inc. (NPCE) reported increase (decrease) in non-cash interest expense of $77K in Q1 2026.
How has Neuropace, Inc.'s increase (decrease) in non-cash interest expense changed year-over-year?
Neuropace, Inc.'s increase (decrease) in non-cash interest expense decreased by 63.8% year-over-year, from $213K to $77K.
What is the long-term trend for Neuropace, Inc.'s increase (decrease) in non-cash interest expense?
Over 4 years (2021 to 2025), Neuropace, Inc.'s increase (decrease) in non-cash interest expense has grown at a -9.6% compound annual growth rate (CAGR), from $806K to $538K.
What does increase (decrease) in non-cash interest expense mean?
This metric represents the portion of interest expense recognized in the income statement that does not involve an immediate cash outflow. It typically includes the amortization of debt discounts, premiums, or issuance costs associated with financial liabilities. Monitoring this helps investors understand the gap between reported interest expense and actual cash interest payments.